Bukwang Pharmaceutical Co., Ltd. (003000.KS)
- Previous Close
6,150.00 - Open
6,170.00 - Bid --
- Ask --
- Day's Range
6,110.00 - 6,190.00 - 52 Week Range
5,460.00 - 9,000.00 - Volume
70,991 - Avg. Volume
682,768 - Market Cap (intraday)
420.996B - Beta (5Y Monthly) -0.12
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Apr 23, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 29, 2021
- 1y Target Est
--
Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, liver cirrhosis, and iron-deficiency anemia; over-the-counter drugs, such as fever and pain relief medication, gastrointestinal medication, cold medication, laxatives for constipation, collagen supplements, multivitamin supplements, mouthwash, topical gels, oral health supplements, and omega-3 supplements; and personal products comprising toothpastes, toothbrushes, and other oral care products; nutraceuticals; health functional foods; and quasi drugs. In addition, it offers products for various threptic areas, including endocrinology, gastroenterology, cardiology, oncology, central nervous system, iron supplements, neuropsychiatry, respiratory/allergy, dermatology, urology, and other treatment areas. Further, the company's development pipeline comprises Lurasidone for the treatment of schizophrenia and bipolar depression; JM-010, for treating dyskinesia in parkinson's disease; SOL-804, which is used for the treatment of metastatic castration resistant prostate cancer; AhR Inhibitor for solid tumors; PKR Inhibitor for neurodegenerative disorders; and PD Program for parkinson's disease. Bukwang Pharmaceutical Co., Ltd. was founded in 1960 and is headquartered in Seoul, South Korea.
www.bukwang.co.kr--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: 003000.KS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 003000.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 003000.KS
Valuation Measures
Market Cap
421.00B
Enterprise Value
349.16B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.34
Price/Book (mrq)
1.86
Enterprise Value/Revenue
2.77
Enterprise Value/EBITDA
-11.10
Financial Highlights
Profitability and Income Statement
Profit Margin
-24.88%
Return on Assets (ttm)
-5.65%
Return on Equity (ttm)
-13.60%
Revenue (ttm)
125.93B
Net Income Avi to Common (ttm)
-31.33B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
151.23B
Total Debt/Equity (mrq)
33.89%
Levered Free Cash Flow (ttm)
59.15B
Company Insights: 003000.KS
003000.KS does not have Company Insights